06 Feb Avita Medical Appoints Dr. Michael S. Perry to Board of Directors
· VP and Senior Global Program Head, Stem Cell Therapy at Novartis Pharmaceuticals
· 25 Years Management Experience in Pharmaceutical and Biotech Development
· Substantial Venture Capital Expertise in Life Science Funds
NORTHRIDGE, Calif., and CAMBRIDGE, United Kingdom,6 February 2013- Regenerative medicine company Avita Medical Ltd. (ASX: AVH), (OTC: AVMXF), (OTCQX: AVMXY) today announced that Dr Michael S. Perry, Vice President and Senior Global Program Head, Stem Cell Therapy at Novartis Pharmaceuticals Corp., has been appointed to the company’s board of directors. Dr Perry has over 25 years of successful pharmaceutical/biotech management and development experience.
Dalton Gooding, Avita Medical chairman, said, “Michael has extraordinary biotech and business expertise, and we are delighted that he is joining Avita’s board of directors.”
Perry currently serves as Vice President and Senior Global Program Head, Stem Cell Therapy at Novartis Pharmaceuticals Corp, a US affiliate of Switzerland-based Novartis AG (NYSE: NVS), a world leader in the research and development of products to protect and improve health and well-being with core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.
Dr Perry, based in the United States, has previously served as the Global Head of R&D at Baxter Healthcare, President, Cell & Gene Therapy at Novartis affiliates SyStemix and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early stage biotech companies.
From 2005 to 2012, Dr Perry was a Venture Partner with Bay City Capital, a California-based venture capital firm managing over US$1.6 billion invested predominantly in life science companies.
“Michael brings a wealth of experience and scientific acumen as well as the insights that come from running successful large global divisions and emerging startups. Michael will be a great addition to our board and I am delighted to be working with him,” said Dr William Dolphin, Avita chief executive officer.
“I am honoured to join the Avita board and work with this exceptional team,” Perry said. “Avita has the potential to make a significant impact in the field of regenerative medicine and I look forward to sharing my experiences and contributing to the future direction and growth at this early stage in the company’s history.”
In addition to Avita Medical, Dr Perry currently serves on the board of two publicly held companies.
ABOUT AVITA MEDICAL LTD.
Avita Medical (http://avitamedical.com/) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita’s patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient’s own skin. The company’s lead product, ReCell® Spray-On Skin™, is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use. An FDA trial on the safety and efficacy of ReCell is in process.